Jung Eric H, Meyers David J, Bosch Jürgen, Casadevall Arturo
Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, New York, USA.
Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
mSphere. 2018 Mar 14;3(2). doi: 10.1128/mSphere.00537-17. eCollection 2018 Mar-Apr.
Similarities in fungal and animal cells make antifungal discovery efforts more difficult than those for other classes of antimicrobial drugs. Currently, there are only three major classes of antifungal drugs used for the treatment of systemic fungal diseases: polyenes, azoles, and echinocandins. Even in situations where the offending fungal organism is susceptible to the available drugs, treatment courses can be lengthy and unsatisfactory, since eradication of infection is often very difficult, especially in individuals with impaired immunity. Consequently, there is a need for new and more effective antifungal drugs. We have identified compounds with significant antifungal activity in the Malaria Box (Medicines for Malaria Ventures, Geneva, Switzerland) that have higher efficacy than some of the currently used antifungal drugs. Our best candidate, MMV665943 (IUPAC name 4-[6-[[2-(4-aminophenyl)-3H-benzimidazol-5-yl]methyl]-1H-benzimidazol-2-yl]aniline), here referred to as DM262, showed 16- to 32-fold-higher activity than fluconazole against . There was also significant antifungal activity in other fungal species with known antifungal resistance, such as and . Antifungal activity was also observed against a common fungus, . These results are important because they offer a potentially new class of antifungal drugs and the repurposing of currently available therapeutics. Much like the recent increase in drug-resistant bacteria, there is a rise in antifungal-resistant strains of pathogenic fungi. There is a need for novel and more potent antifungal therapeutics. Consequently, we investigated a mixed library of drug-like and probe-like compounds with activity in spp. for activity against two common fungal pathogens, and , along with two less common pathogenic species, and . We uncover a previously uncharacterized drug with higher broad-spectrum antifungal activity than some current treatments. Our findings may eventually lead to a compound added to the arsenal of antifungal therapeutics.
真菌细胞与动物细胞的相似性使得抗真菌药物的研发工作比其他类别的抗菌药物更加困难。目前,仅有三大类抗真菌药物用于治疗全身性真菌疾病:多烯类、唑类和棘白菌素类。即便在致病真菌对现有药物敏感的情况下,治疗疗程往往也很长且效果不尽人意,因为根除感染通常非常困难,尤其是在免疫力受损的个体中。因此,需要新的、更有效的抗真菌药物。我们在疟疾药物盒(瑞士日内瓦的疟疾药物风险投资公司)中鉴定出了具有显著抗真菌活性的化合物,其疗效高于一些目前使用的抗真菌药物。我们最有潜力的候选药物MMV665943(国际纯粹与应用化学联合会命名:4-[6-[[2-(4-氨基苯基)-3H-苯并咪唑-5-基]甲基]-1H-苯并咪唑-2-基]苯胺),此处称为DM262,对……显示出比氟康唑高16至32倍的活性。在其他已知具有抗真菌耐药性的真菌物种中,如……和……,也存在显著的抗真菌活性。对一种常见真菌……也观察到了抗真菌活性。这些结果很重要,因为它们提供了一类潜在的新型抗真菌药物以及现有治疗药物的新用途。与最近耐药细菌的增加情况非常相似,致病真菌的抗真菌耐药菌株也在增多。需要新型且更有效的抗真菌治疗药物。因此,我们研究了一组在……物种中具有活性的类药物和类探针化合物的混合文库,以检测其对两种常见真菌病原体……和……以及两种不太常见的致病物种……和……的活性。我们发现了一种以前未被表征的药物,其广谱抗真菌活性高于一些目前的治疗药物。我们的发现最终可能会使一种化合物被添加到抗真菌治疗药物的 arsenal中。